BioFactura Announces MTA with Rani Therapeutics

Published on :

BioFactura Inc. (“BioFactura”), a leading developer of high-value biosimilar and biodefense drugs using its patented StableFast™ platform, announces an agreement with Rani Therapeutics (“Rani”) to assess its Ustekinumab Biosimilar (BFI-751) in combination with Rani’s RaniPill™ platform.

BioFactura Announces Initiation of Phase I Study of BFI-751, a Stelara® (ustekinumab) Biosimilar

Published on :

BioFactura, a leading developer of high-value biosimilar and biodefense drugs using its patented StableFastTM platform, announces today the initiation of a pivotal PK (pharmacokinetics) Phase 1 Clinical Trial for its Ustekinumab Biosimilar (BFI-751), to assess the effects on healthy human volunteers compared to the biologic medicine, Stelera®. This is the first time BFI-751 has been administered to humans, as authorized by the Ethics Committees in both Australia and New Zealand.

BioFactura Funded $13 Million Contract Option for its Smallpox Biodefense Therapeutic

Published on :

BioFactura, Inc. today announced a contract option activation of over $13 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, as part of BioFactura’s prime contract

BioFactura Awarded $67.4 Million Advanced Development Contract for its Smallpox Biodefense Therapeutic

Published on :

BioFactura Awarded $67.4 Million Advanced Development Contract for its Smallpox Biodefense Therapeutic Frederick, Maryland, September 26, 2019:  BioFactura, Inc. today announced a contract awarded by the Biomedical Advanced Research and [….]

BioFactura CEO Dr. Darryl Sampey Shares his Entrepreneurial Journey at Frederick’s StartupGrind Event

Published on :

BioFactura CEO Dr. Darryl Sampey Shares his Entrepreneurial Journey at Frederick’s StartupGrind Event February 26, 2019 Dr. Darryl Sampey has been through the grind as CEO of Frederick’s BioFactura, a [….]